Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.51 USD | +1.19% |
|
+1.19% | -18.09% |
06-17 | Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy | MT |
06-17 | Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.09% | 607M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Citigroup Lowers Zymeworks Price Target to $28 From $30, Buy Rating Kept